MedTrace Logo

Additive Effects of QVAR to (Seretide) on Surrogate Markers of Airway Inflammation in Refractory Asthma

NCT00829257 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2019-04-12

No results posted yet for this study

Summary

The purpose of this study is to establish whether addition of extra-fine particle steroid inhalers achieve additional suppression of small airways inflammation when added to 'standard' Fluticasone/Salmeterol combination therapy in refractory asthma.

Conditions

Interventions

DRUG

HFA-BDP

HFA-BDP (Qvar) 100ug 2puff b.i.d

DRUG

Fluticasone

Fluticasone propionate Accuhaler 250ug b.i.d.

DRUG

Seretide

Fluticasone/Salmeterol (Seretide) 500/50ug, 1 puff b.i.d

Sponsors & Collaborators

  • University of Dundee

    lead OTHER

Principal Investigators

  • Peter A Williamson · University of Dundee

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2010-07-31
Completion
2010-07-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00829257 on ClinicalTrials.gov